Intellia Therapeutics (NTLA) Total Current Liabilities (2015 - 2026)
Intellia Therapeutics (NTLA) posted quarterly Total Current Liabilities of $76.4 million for Q1 2026, down 32.11% year-over-year from $112.6 million in Q1 2025, and down 26.41% quarter-over-quarter from $103.9 million in Q4 2025.
Intellia Therapeutics (NTLA) Total Current Liabilities (2015 - 2026) Analysis & Trends
Intellia Therapeutics (NTLA) has reported Total Current Liabilities for 12 consecutive years, with $76.4 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Total Current Liabilities fell 32.11% year-over-year to $76.4 million; the TTM figure through Mar 2026 stood at $76.4 million (down 32.11% YoY), while the FY2025 annual figure was $103.9 million, down 6.29% from the prior year.
- Total Current Liabilities fell to $76.4 million in Q1 2026 per NTLA's latest filing, from $103.9 million in the prior quarter.
- Across five years, Total Current Liabilities topped out at $131.1 million in Q3 2022 and bottomed at $76.4 million in Q1 2026.
- Historically, Total Current Liabilities has averaged $107.0 million across 5 years, with a median of $105.1 million in 2024.
- Annual changes were most pronounced in 2022 — Total Current Liabilities jumped 107.75% — and 2026, when it sank 32.11%.
- Intellia Therapeutics' Total Current Liabilities stood at $126.6 million in 2022, then declined by 8.97% to $115.2 million in 2023, then dropped by 3.78% to $110.9 million in 2024, then declined by 6.29% to $103.9 million in 2025, then slipped by 26.41% to $76.4 million in 2026.
- Business Quant data shows NTLA's Total Current Liabilities at $76.4 million in Q1 2026, $103.9 million in Q4 2025, and $93.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.58 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 354.06 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 2.12 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 4.22 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 630.93 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.51 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 438.74 Mn |
| 10 | Intellia Therapeutics | 1.67 Bn | 1.67 Bn | - | 79.39 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 79.39 Mn |
| Mar 31, 2026 | 76.45 Mn |
| Dec 31, 2025 | 103.88 Mn |
| Sep 30, 2025 | 93.73 Mn |
| Jun 30, 2025 | 95.50 Mn |
| Mar 31, 2025 | 112.59 Mn |
| Dec 31, 2024 | 110.85 Mn |
| Sep 30, 2024 | 105.68 Mn |
| Jun 30, 2024 | 105.09 Mn |
| Mar 31, 2024 | 97.91 Mn |
| Dec 31, 2023 | 115.21 Mn |
| Sep 30, 2023 | 91.95 Mn |
| Jun 30, 2023 | 99.85 Mn |
| Mar 31, 2023 | 103.38 Mn |
| Dec 31, 2022 | 126.55 Mn |
| Sep 30, 2022 | 131.13 Mn |
| Jun 30, 2022 | 123.76 Mn |
| Mar 31, 2022 | 126.11 Mn |
| Dec 31, 2021 | 125.83 Mn |
| Sep 30, 2021 | 97.57 Mn |